| Phase III Study Showed Tarceva in Combination with Avastin as First-Line Maintenance Therapy Improved Progression-Free ... (Business Wire via Yahoo! Finance) |
|
|
MELVILLE, N.Y.----OSI Pharmaceuticals, Inc. announced today that its U.S. partner for Tarceva® , Genentech, Inc., informed OSI that a Genentech conducted Phase III study, ATLAS, was stopped early on the recommendation of an independent data safety monitoring board. |